HRP20191373T1 - Pripravci koji sadrže amlodipin i bisoprolol - Google Patents
Pripravci koji sadrže amlodipin i bisoprolol Download PDFInfo
- Publication number
- HRP20191373T1 HRP20191373T1 HRP20191373T HRP20191373T1 HR P20191373 T1 HRP20191373 T1 HR P20191373T1 HR P20191373 T HRP20191373 T HR P20191373T HR P20191373 T1 HRP20191373 T1 HR P20191373T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- amlodipine
- blister
- packed
- preparation
- Prior art date
Links
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title claims 8
- 229960000528 amlodipine Drugs 0.000 title claims 3
- 239000000203 mixture Substances 0.000 title claims 2
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 title 1
- 229960002781 bisoprolol Drugs 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 12
- -1 polypropylene Polymers 0.000 claims 9
- 238000002360 preparation method Methods 0.000 claims 9
- RZPZLFIUFMNCLY-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol Chemical compound OC(=O)\C=C\C(O)=O.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 RZPZLFIUFMNCLY-WLHGVMLRSA-N 0.000 claims 8
- 229960005400 bisoprolol fumarate Drugs 0.000 claims 8
- 239000011888 foil Substances 0.000 claims 7
- 239000004743 Polypropylene Substances 0.000 claims 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 6
- 229910052782 aluminium Inorganic materials 0.000 claims 6
- 239000002775 capsule Substances 0.000 claims 6
- 239000002131 composite material Substances 0.000 claims 6
- 229920001155 polypropylene Polymers 0.000 claims 6
- 239000007884 disintegrant Substances 0.000 claims 5
- 239000000314 lubricant Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims 4
- 229960004005 amlodipine besylate Drugs 0.000 claims 4
- 239000000945 filler Substances 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 239000004698 Polyethylene Substances 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000010408 film Substances 0.000 claims 3
- 239000011521 glass Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229920000573 polyethylene Polymers 0.000 claims 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000000181 anti-adherent effect Effects 0.000 claims 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 2
- 239000013039 cover film Substances 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 238000004806 packaging method and process Methods 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000007907 direct compression Methods 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 238000000265 homogenisation Methods 0.000 claims 1
- 239000011256 inorganic filler Substances 0.000 claims 1
- 229910003475 inorganic filler Inorganic materials 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000000465 moulding Methods 0.000 claims 1
- 239000012766 organic filler Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Claims (14)
1. Stabilni čvrsti farmaceutski pripravak, naznačen time što sadrži homogeniziranu praškastu smjesu amlodipinske baze, ili njezine farmaceutski prihvatljive soli, i bisoprolol-fumarata, kao i farmaceutski prihvatljivih pomoćnih tvari, pakiranih u pakiranje otporno na vlagu i koje dodatno sadrži manje od 0,5% spoja formule
na osnovi težine aktivnih sastojaka, gdje pripravak dodatno sadrži organsko ili anorgansko punilo, sredstvo za raspadanje, mazivo i izborno vezivo.
2. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što pripravak sadrži amlodipin-besilat.
3. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što pripravak sadrži manje od 0,3% spoja formule (3).
4. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što pripravak sadrži manje od 0,2% spoja formule (3).
5. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što se pripravak pakira u hladno oblikovani blister (tzv. hladni blister /CFF/) od OPA/AL/PVC kompozitne folije pokrivene aluminijskom pokrovnom folijom.
6. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što se pripravak pakira u blister od toplo oblikovane kompozitne folije otporne na vlagu, te pokriva aluminijskom pokrovnom folijom.
7. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što se pripravak pakira u staklenu ili polipropilensku posudu opremljenu hermetički zatvarajućim spremničkim poklopcem od polietilena ili polipropilena.
8. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačen time što je tableta ili kapsula.
9. Farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačen time što se tabletu pakira u pakiranje otporno na vlagu, naznačen time što sadrži 2%-20%, po mogućnosti 2%-10%, poželjnije, 1-6% amlodipin-besilata, 2%-20%, po mogućnosti 2%-10%, poželjnije 1%-6% bisoprolol-fumarata, te što dodatno sadrži 60%-90%, po mogućnosti 70%-90%, poželjnije 80%-90% punila, 1%-10%, po mogućnosti 4%-6% sredstva za raspadanje, 0,5%-3%, po mogućnosti 1%-2% maziva, 0,3%-2%, po mogućnosti 0,1%-5% veziva na osnovi težine tablete.
10. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što se tabletu pakira u hladno oblikovani blister (tzv. hladni blister /CFF/) od OPA/AL/PVC kompozitne folije pokrivene aluminijskom pokrovnom folijom, ili u blister od kompozitne folije otporne na vlagu pogodne za toplo oblikovanje, te pokriva aluminijskom pokrovnom folijom, ili u staklenu ili polipropilensku posudu opremljenu hermetički zatvarajućim spremničkim poklopcem od polietilena ili polipropilena, što sadrži 1%-6% amlodipin-besilata, 1%-6% bisoprolol-fumarata, 80%-90% mikrokristalne celuloze, 4%-6% karboksimetilškrob-natrija, 1%-2% magnezijevog stearata, 0,5%-1% koloidnog silicijevog dioksida na osnovi težine tablete.
11. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što je kapsula pakirani into a hladno oblikovani blister (tzv. hladni blister /CFF/) od OPA/AL/PVC kompozitne folije pokrivene aluminijskom pokrovnom folijom, ili u blister od thermoformable kompozitna folija otporna na vlagu, te pokriva aluminijskom pokrovnom folijom, ili u staklenu ili polipropilensku posudu opremljenu hermetički zatvarajućim spremničkim poklopcem od polietilena ili polipropilena, što sadrži 10%-15% amlodipin-besilata, 10%-15% bisoprolol-fumarata, dodatno 55%-65% mikrokristalne celuloze, 4%-6% karboksimetilškrob-natrija, 1%-2% magnezijevog stearata, 0,5%-1% koloidnog silicijevog dioksida na osnovi težine tvari za punjenje kapsule.
12. Postupak priprave stabilnog čvrstog farmaceutskog pripravka koji sadrži amlodipinsku bazu, ili njezinu farmaceutski prihvatljivu sol, i bisoprolol-fumarat, naznačen time što se amlodipinsku bazu, ili njezina farmaceutski prihvatljivu sol, i bisoprolol-fumarat, sredstvo za raspadanje, mazivo i po potrebi dodatne pomoćne tvari koje se upotrebljava u farmaceutskoj industriji homogenizira, zatim se doda antiadheziv, nastavi s homogeniziranjem, te se
a.) homogenizat komprimira u tablete postupkom izravnog komprimiranja ili,
b.) puni u tvrde želatinske kapsule na poznati način,
zatim se dobivene tablete ili kapsule pakira u zaštitna pakiranja otporna na vlagu na poznati način.
13. Postupak priprave tableta u skladu s patentnim zahtjevom 12, naznačen time što se upotrebljava 2%-20%, po mogućnosti 2%-10%, poželjnije 1-6% amlodipinske baze, ili njezine farmaceutski prihvatljive adicijske soli s kiselinom, po mogućnosti amlodipin-besilata, 2%-20%, po mogućnosti 2%-10%, poželjnije 1%-6% bisoprolol-fumarata, dodatno 60%-90%, po mogućnosti 70%-90%, poželjnije 80%-90% punila, 1%-10%, po mogućnosti 4%-6% sredstva za raspadanje, 0,5%-3%, po mogućnosti 1%-2% maziva, 0,3%-2%, po mogućnosti 1%-10%, po mogućnosti 0,5%-1% veziva na osnovi težine tablete.
14. Postupak priprave kapsula u skladu s patentnim zahtjevom 12, naznačen time što se upotrebljava 5%-80%, po mogućnosti 5%-18%, poželjnije, 10-15% amlodipinske baze, ili njezine farmaceutski prihvatljive adicijske soli s kiselinom, po mogućnosti amlodipin-besilata, 5%-80%, po mogućnosti 5%-15%, poželjnije 10%-15% bisoprolol-fumarata, dodatno 1%-10%, po mogućnosti 4%-6% sredstva za raspadanje, 0,5%-3%, po mogućnosti 1%-2% maziva, 0,3%-2%, po mogućnosti 0,5%-1% antiadhezivnog sredstva, te po potrebi 10%-75%, po mogućnosti 45%-75%, poželjnije 55%-65% punila na osnovi težine tvari za punjenje kapsule.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0800591A HU230877B1 (hu) | 2008-09-30 | 2008-09-30 | Stabil kombinációs gyógyszerkészítmény |
| PCT/HU2009/000085 WO2010038091A2 (en) | 2008-09-30 | 2009-09-30 | Stable combination pharmaceutical composition |
| EP09748467.9A EP2344141B1 (en) | 2008-09-30 | 2009-09-30 | Compositions comrrising amlodipine and bisoprolol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191373T1 true HRP20191373T1 (hr) | 2019-11-01 |
Family
ID=89988527
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20110162AA HRP20110162B1 (hr) | 2008-09-30 | 2011-03-04 | Spojevi koji sadrže amlodipin i bisoprolol |
| HRP20191373 HRP20191373T1 (hr) | 2008-09-30 | 2019-07-31 | Pripravci koji sadrže amlodipin i bisoprolol |
| HRP20200614TT HRP20200614T1 (hr) | 2008-09-30 | 2020-04-08 | Pripravci koji sadrže amlodipin i bisoprolol |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20110162AA HRP20110162B1 (hr) | 2008-09-30 | 2011-03-04 | Spojevi koji sadrže amlodipin i bisoprolol |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200614TT HRP20200614T1 (hr) | 2008-09-30 | 2020-04-08 | Pripravci koji sadrže amlodipin i bisoprolol |
Country Status (31)
| Country | Link |
|---|---|
| EP (2) | EP2344141B1 (hr) |
| KR (1) | KR101772619B1 (hr) |
| CN (1) | CN102164585B (hr) |
| AT (2) | AT14769U1 (hr) |
| BG (1) | BG66274B1 (hr) |
| CH (1) | CH702345B1 (hr) |
| CY (1) | CY1122084T1 (hr) |
| CZ (2) | CZ30825U1 (hr) |
| DE (1) | DE202009019152U1 (hr) |
| DK (1) | DK2344141T3 (hr) |
| EA (2) | EA038392B1 (hr) |
| EE (1) | EE05723B1 (hr) |
| ES (2) | ES2739900T3 (hr) |
| GE (1) | GEP20135859B (hr) |
| HK (1) | HK1155976A1 (hr) |
| HR (3) | HRP20110162B1 (hr) |
| HU (3) | HU230877B1 (hr) |
| LT (3) | LT2344141T (hr) |
| ME (1) | ME03774B (hr) |
| MX (1) | MX2011003407A (hr) |
| MY (1) | MY175270A (hr) |
| PL (3) | PL2344141T3 (hr) |
| PT (3) | PT2344141T (hr) |
| RO (1) | RO127490B1 (hr) |
| RS (3) | RS60784B1 (hr) |
| RU (2) | RU2687282C2 (hr) |
| SG (1) | SG194392A1 (hr) |
| SI (2) | SI2359815T1 (hr) |
| SK (2) | SK7997Y1 (hr) |
| UA (1) | UA101407C2 (hr) |
| WO (1) | WO2010038091A2 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU230877B1 (hu) | 2008-09-30 | 2018-11-29 | EGIS Gyógyszergyár NyR | Stabil kombinációs gyógyszerkészítmény |
| CN101766611B (zh) * | 2010-02-09 | 2011-10-12 | 施慧达药业集团(吉林)有限公司 | 一种左旋氨氯地平或其可药用盐和β受体阻滞剂的药物组合物及其应用 |
| UA113977C2 (xx) | 2012-02-17 | 2017-04-10 | Фармацевтична композиція з покращеною стабільністю | |
| CA3151685A1 (en) * | 2013-06-13 | 2014-12-18 | Akebia Therapeutics, Inc. | Compositions and methods for treating anemia |
| HUP1300496A2 (hu) | 2013-08-16 | 2015-03-02 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Stabil kombinációs gyógyszerkészítmény |
| FR3027803B1 (fr) * | 2014-11-05 | 2018-02-09 | Les Laboratoires Servier | Composition pharmaceutique comprenant un betabloquant et un inhibiteur de l'enzyme de conversion |
| FR3050380B1 (fr) | 2016-04-20 | 2020-07-10 | Les Laboratoires Servier | Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains. |
| WO2024052498A1 (en) | 2022-09-07 | 2024-03-14 | Kinast Lasse | An immediate-release oral pharmaceutical form of amlodipine with increased api content |
| CN116687926B (zh) * | 2023-07-27 | 2023-12-12 | 石家庄四药有限公司 | 一种比索洛尔氨氯地平复方片剂及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU221810B1 (hu) * | 1997-08-12 | 2003-01-28 | EGIS Gyógyszergyár Rt. | Eljárás amlodipin-bezilát előállítására és az eljárás intermedierjei |
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| AT5874U1 (de) * | 2000-12-29 | 2003-01-27 | Bioorg Bv | Pharmazeutische zubereitungen enthaltend amlodipinmaleat |
| CA2433181C (en) | 2000-12-29 | 2005-11-22 | Pfizer Limited | Amlodipine hemifumarate |
| AU2001100431A4 (en) * | 2001-10-03 | 2001-11-01 | Pfizer Limited | Pharmaceutical compositions comprising amlodipine maleate |
| WO2003032954A1 (en) | 2001-10-17 | 2003-04-24 | Dr. Reddy's Laboratories Ltd. | Stabilized pharmaceutical formulations containing amlodipine maleate |
| WO2004075825A2 (en) * | 2003-02-28 | 2004-09-10 | Ranbaxy Laboratories Limited | Dosage forms of amlodipine and processes for their preparation |
| WO2005051350A2 (en) * | 2003-10-28 | 2005-06-09 | Torrent Pharmaceuticals Limited | Water dispersible tablet |
| WO2005099699A1 (en) * | 2004-04-07 | 2005-10-27 | Sepracor Inc. | Combination of (s)-amlodipine and a beta-blocker, and methods for reducing hypertension |
| IN224215B (hr) * | 2004-08-05 | 2009-02-06 | ||
| WO2006059217A1 (en) * | 2004-12-01 | 2006-06-08 | Ranbaxy Laboratories Limited | Stable solid dosage forms of amlodipine besylate and processes for their preparation |
| CZ2005141A3 (cs) * | 2005-03-07 | 2006-04-12 | Lunaria, Spol. S. R. O. | Lécivý prípravek na bázi amlodipin-besilátu se zvýsenou stabilitou |
| IES20070122A2 (en) * | 2006-12-05 | 2008-05-28 | Michael Hilary Burke | A process for the preparation of an orally administered unit dose tablet |
| HU230877B1 (hu) | 2008-09-30 | 2018-11-29 | EGIS Gyógyszergyár NyR | Stabil kombinációs gyógyszerkészítmény |
-
2008
- 2008-09-30 HU HU0800591A patent/HU230877B1/hu unknown
-
2009
- 2009-09-30 SI SI200932053T patent/SI2359815T1/sl unknown
- 2009-09-30 PT PT09748467T patent/PT2344141T/pt unknown
- 2009-09-30 HU HUE09748467A patent/HUE045326T2/hu unknown
- 2009-09-30 RS RS20200397A patent/RS60784B1/sr unknown
- 2009-09-30 ES ES09748467T patent/ES2739900T3/es active Active
- 2009-09-30 EP EP09748467.9A patent/EP2344141B1/en not_active Revoked
- 2009-09-30 HU HUE11003486A patent/HUE049948T2/hu unknown
- 2009-09-30 MY MYPI2011001388A patent/MY175270A/en unknown
- 2009-09-30 PT PT2009000085A patent/PT2010038091Y/pt active IP Right Grant
- 2009-09-30 ME MEP-2020-76A patent/ME03774B/me unknown
- 2009-09-30 ES ES201190015A patent/ES2385988B2/es active Active
- 2009-09-30 EP EP11003486.5A patent/EP2359815B1/en active Active
- 2009-09-30 PL PL09748467T patent/PL2344141T3/pl unknown
- 2009-09-30 SK SK7-2017U patent/SK7997Y1/sk unknown
- 2009-09-30 CZ CZ2017-33281U patent/CZ30825U1/cs not_active IP Right Cessation
- 2009-09-30 DE DE202009019152.4U patent/DE202009019152U1/de not_active Expired - Lifetime
- 2009-09-30 EA EA201691869A patent/EA038392B1/ru unknown
- 2009-09-30 PL PL394605A patent/PL394605A1/pl unknown
- 2009-09-30 SK SK5023-2011A patent/SK288593B6/sk unknown
- 2009-09-30 MX MX2011003407A patent/MX2011003407A/es not_active Application Discontinuation
- 2009-09-30 EE EEP201100029A patent/EE05723B1/et unknown
- 2009-09-30 RS RS20110136A patent/RS60686B1/sr unknown
- 2009-09-30 GE GEAP200912210A patent/GEP20135859B/en unknown
- 2009-09-30 SG SG2013073382A patent/SG194392A1/en unknown
- 2009-09-30 AT ATGM8014/2015U patent/AT14769U1/de not_active IP Right Cessation
- 2009-09-30 WO PCT/HU2009/000085 patent/WO2010038091A2/en active Application Filing
- 2009-09-30 EA EA201100430A patent/EA026238B9/ru not_active IP Right Cessation
- 2009-09-30 AT ATA9359/2009A patent/AT510866A3/de active IP Right Grant
- 2009-09-30 CH CH00567/11A patent/CH702345B1/de unknown
- 2009-09-30 DK DK09748467.9T patent/DK2344141T3/da active
- 2009-09-30 SI SI200931990T patent/SI2344141T1/sl unknown
- 2009-09-30 CN CN200980138060.7A patent/CN102164585B/zh active Active
- 2009-09-30 KR KR1020117009405A patent/KR101772619B1/ko active IP Right Grant
- 2009-09-30 UA UAA201105446A patent/UA101407C2/ru unknown
- 2009-09-30 LT LTEP09748467.9T patent/LT2344141T/lt unknown
- 2009-09-30 PT PT110034865T patent/PT2359815T/pt unknown
- 2009-09-30 CZ CZ2011-252A patent/CZ308237B6/cs unknown
- 2009-09-30 RO RO201100274A patent/RO127490B1/ro unknown
- 2009-09-30 RS RSP20190990 patent/RS59201B1/sr unknown
- 2009-09-30 RU RU2014139476A patent/RU2687282C2/ru active
- 2009-09-30 PL PL11003486T patent/PL2359815T3/pl unknown
- 2009-09-30 RU RU2011112047/15A patent/RU2549437C2/ru active
- 2009-09-30 LT LTEP11003486.5T patent/LT2359815T/lt unknown
-
2011
- 2011-02-24 LT LT2011012A patent/LT5815B/lt unknown
- 2011-03-04 HR HRP20110162AA patent/HRP20110162B1/hr active IP Right Grant
- 2011-04-29 BG BG10110927A patent/BG66274B1/bg unknown
- 2011-10-03 HK HK11110411.7A patent/HK1155976A1/zh unknown
-
2019
- 2019-07-30 CY CY20191100810T patent/CY1122084T1/el unknown
- 2019-07-31 HR HRP20191373 patent/HRP20191373T1/hr unknown
-
2020
- 2020-04-08 HR HRP20200614TT patent/HRP20200614T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191373T1 (hr) | Pripravci koji sadrže amlodipin i bisoprolol | |
| MX2011003510A (es) | Metodo para fabricar un laminado adhesivo de multiples capas. | |
| CA2663941C (en) | Stabilized solid forms and method for the production thereof | |
| RU2015144543A (ru) | Фармацевтические композиции, содержащие активное вещество | |
| AU2016203632A1 (en) | Pack of medicinal tablets | |
| WO2006101462A2 (en) | Pharmaceutical preparation comprising perindopril erbumine and method of preparation and stabilisation thereof | |
| EP2404588A1 (en) | Package of solid pharmaceutical preparation | |
| EP2949319A1 (en) | Pharmaceutical compositions comprising an active agent | |
| Begadilova et al. | PRODUCTION OF A MEDICINE BASED ON LEVOMICETIN IN A CAPSULATED FORM | |
| TW202038906A (zh) | 醫藥品 | |
| TH132946A (th) | ห่อบรรจุ |